Supplementary Online Content

Ortigoza MB, Yoon H, Goldfeld KS, et al; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. *JAMA Intern Med*. Published online December 13, 2021. doi:10.1001/jamainternmed.2021.6850

eMethods. Expanded Methods

eTable 1. Summary of Posterior Predictive Checks for 10 Test Statistics Based on 10,000 Replicated Datasets

eTable 2. Baseline Characteristics by Enrollment Sites and Treatment Group

eTable 3. Baseline Patient Characteristics by Enrollment Quarter

eTable 4. Cumulative Odds Model of WHO Scores at Day 14 by Subgroups

eTable 5. Odds Ratios for Mortality at Day 14 by Subgroups

eTable 6. Cumulative Odds Model of WHO Scores at Day 28 by Subgroups

eTable 7. Odds Ratio for Mortality at Day 28 by Subgroups

eTable 8. Baseline Patient Characteristics by Remdesivir Use at Randomization

eTable 9. Baseline Patient Characteristics by Corticosteroids Use at Randomization

eTable 10. CCP SARS-CoV-2 IgG and Neutralizing Titors by Quarters of Enrollment

eTable 11. Baseline Characteristics and Day 14/28 Outcomes by Baseline SARS-CoV-2 IgG Status and Treatment Group

eTable 12. Adverse Events and Serious Adverse Events

eFigure 1. Trace Plots of Model Convergence

eFigure 2. Observed Cumulative Probability With Predicted 95% Credible Interval by Treatment Group

eFigure 3. Clinical Outcomes Among Patients Treated With Convalescent Plasma and Placebo 14 and 28 Days After Randomization by Enrollment Quarter

eFigure 4. Cumulative OR for WHO Ordinal Scale and OR for Mortality at Day 14 in Indicated Subgroups

eFigure 5. Cumulative OR for WHO Ordinal Scale and OR for Mortality at Day 14 in Indicated Subgroups

eFigure 6. Posterior Probability of Mortality at Day 14 of Placebo and CCP Recipients in Indicated Subgroups Without Adjustment for any Covariates

eFigure 7. Posterior Probability of Mortality at Day 28 of Placebo and CCP Recipients in Indicated Subgroups Without Adjustment for any Covariates

eFigure 8. Clinical Outcome in Placebo and CCP Groups Dichotomized by Median CCP SARS-CoV-2 IgG EC50 at 14 and 28 Days After Randomization

eReferences

This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods. (Expanded methods)

1. Race and ethnicity data sources
Collection of race and ethnicity data in this study was required by the funding agency, the National Center for Advancing Translational Sciences of the National Institutes of Health, consistent with the inclusion of women and minorities policy. Race and ethnicity data were obtained from entries in the medical record, as reported by the participants, using fixed categories. Individuals participating in the study were categorized as Asian, Hispanic, non-Hispanic Black, non-Hispanic White, other, and unknown. ‘Other’ included mixed race, American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Race and ethnicity data were included to provide additional information about participants included in the study and the potential generalizability of the results.

2. Primary and secondary outcome assessments
The primary outcome was clinical status 14 days after randomization assessed with the 11-point WHO Ordinal Scale for Clinical Improvement. For patients who remained hospitalized 14 days after randomization, primary outcome ascertainment was determined by medical record review. For patients who were discharged prior to 14 days after randomization, primary outcome ascertainment was determined through a telephone follow up. Patients who could not be reached by telephone for the primary outcome assessment at day 14 had the ordinal score carried forward from the date of discharge. The secondary outcome was clinical status 28 days after randomization assessed with the 11-point WHO Ordinal Scale for Clinical Improvement. As above, the secondary outcome ascertainment was determined by medical record review for patients hospitalized or by telephone follow up for discharged participants. Participants who
could not be reached by telephone for the secondary outcome assessment at day 28 were marked as “not done”.

3. COVID-19 Convalescent Plasma (CCP) procurement, storage and transfusion

CCP used at Montefiore Medical Center/Albert Einstein College of Medicine (Montefiore/Einstein) was obtained by an institution donor program conducted in March-April 2020 as described previously². Briefly, after obtaining informed consent, blood was collected between March and April 2020 from otherwise healthy adult volunteers residing in Westchester County, Rockland County, and the Bronx, New York, who had recovered from mild to moderate COVID-19 that did not require hospitalization. Potential donors had a documented positive nasopharyngeal swab by polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during illness and had been asymptomatic for at least 14 days prior to sample collection. Serum was obtained by venipuncture (BD Vacutainer, serum), aliquoted, heat-inactivated at 56°C for 30 minutes and stored at 4°C prior to antibody screening by enzyme-linked immunosorbent assay (ELISA). Donors with SARS-CoV-2 spike protein titers > 1:1,000 on an in-house full length spike protein ELISA³ were referred for apheresis at the New York Blood Center (NYBC). CCP units were sent from the NYBC to the Montefiore Medical Center (MMC) blood bank on the Moses Campus for storage. These units were used at MMC from May 4, 2020, when the trial launched at Einstein/Montefiore until January 15, 2021, when the trial switched to NYBC high titer plasma having a signal-to-cutoff ratio ≥12 on the Ortho V platform⁴.
For all other CONTAIN COVID-19 sites, CCP was provided by the NYBC and was collected from donors with a positive anti-SARS-CoV-2 antibody test measured by the New York SARS-CoV-2 Microsphere Immunoassay at the NYBC\(^5\). Beginning in January 2021, all sites used CCP that was qualified by the NYBC as ‘high titer’ using the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG platform with signal-to-cutoff ratio \(\geq 12\) as per FDA guidance\(^4\).

Plasma recipients were transfused with 1 unit (approximately 200-250 mL) of ABO-type matched CCP over 2–3 hours and monitored before, during, and after infusion for signs of transfusion-related reactions per standard transfusion protocol. Individual institutional guidelines or standard operating procedure (SOP) for the administration of CCP were followed, including the use of any pre-medications, such as acetaminophen and diphenhydramine. Post-treatment management of fluid overload was provided on a case-by-case basis.

4. **SARS-CoV-2 spike protein IgG titers of convalescent (donor) plasma and patient plasma before transfusion of study product**

CCP bag segments (CCP segments, remnant tubing-containing plasma) were removed locally at the blood bank of each site during thawing of CCP bag and kept at 4°C. CCP segments were used to avoid CCP bag compromise which would pose a risk of contamination to participants. These segments were shipped from local trial sites to the Montefiore/Einstein Biorepository where they were aliquoted, frozen, and thawed for retrospective determination of spike protein IgG and pseudovirus neutralization. The SARS-CoV-2 spike ectodomain IgG titer in 406 administered CCP units was determined retrospectively by the Montefiore/Einstein in house ELISA\(^3,6,7\).
Participant SARS-CoV-2 spike protein-binding IgG titers were determined on plasma samples obtained prior to transfusion of CCP or placebo using the Montefiore/Einstein spike ectodomain protein ELISA as described previously. Titers are reported as half-maximal effective concentration (EC$_{50}$) values derived by a curve fitting model as follows: First, each experimental repeat was processed independently by subtracting the corresponding background noise and normalizing the Optical Densities (OD) relative to a positive control. For each experimental repeat, background noise was inferred by considering the lowest OD readout. Following this, we jointly processed denoised and normalized ODs to fit a single sigmoidal curve (using least-squares minimization) and estimate the corresponding EC$_{50}$/IC$_{50}$:

$$y = y_{\text{min}} + (y_{\text{max}} - y_{\text{min}})/\left[1 + 10^{(\log_{10}\text{EC}_{50}-x)\times\text{Hill}}\right]$$

Where $y$ corresponds to the OD (denoised and normalized); $y_{\text{min}}$ and $y_{\text{max}}$ are the minimum and maximum ODs, respectively; EC$_{50}$ is the titer that gives half-maximum absorbance, $y_{\text{max}}$; Hill describes the slope of the curve, and $x$ is the log$_{10}$ (1/dilution). Curve fitting of ELISA readouts was performed by constraining $y_{\text{min}}$ to 0.

5. **Recombinant vesicular stomatitis virus (VSV)-SARS-CoV-2 S neutralization assay**

The neutralization assay was performed as previously described. Results are reported as EC$_{50}$ values as done with SARS-CoV-2 IgG above with the exception that in the case of neutralization readouts, we constrained $y_{\text{min}}$ and $y_{\text{max}}$ to be between 0-100 and 0-150 respectively.
6. Statistical analysis of CCP and participant SARS-CoV-2 IgG and CCP neutralization titers

All randomized participants in the placebo group, and all CCP recipients who had CCP IgG titer measured were included in the analysis of SARS-CoV-2 IgG titers in accordance with their randomization arm, except for participants who fully withdrew informed consent or those whose blood samples could not be obtained for SARS-CoV-2 IgG testing. We evaluated the association between treatment arm and the WHO ordinal outcome using a cumulative odds model and mortality using a logistic regression model at days 14 and 28. To investigate the dose response, we analyzed the log transformed IgG titer, neutralization data, and segmentation EC$_{50}$ adjusting for pre-specified covariates, age, sex, WHO score at randomization, and symptom duration. For neutralization data, we dichotomized patients in the CCP group using different cut off points (1:80/1:160/1:320). We also performed subgroup analysis within the patient groups that were not receiving remdesivir or corticosteroids, tested the interactions between the high/low neutralization group with remdesivir or corticosteroids use, and enrollment quarter respectively. For segment EC$_{50}$, CCP group was dichotomized at the median IgG EC$_{50}$ value and association between the three treatment arms (placebo, intervention group with CCP EC$_{50}$ below the median (low EC$_{50}$), and intervention group with CCP EC$_{50}$ above the median (high EC$_{50}$)) with the outcome was evaluated.

In addition, we evaluated the association between baseline SARS-CoV-2 IgG EC$_{50}$ and outcomes. Participants were categorized as seronegative or seropositive using a baseline IgG EC$_{50}$ cutoff of 1:100. IgG EC$_{50}$s were log-transformed for the analysis. To investigate the effect of baseline antibody on treatment benefit, we tested the interaction between baseline antibody status with the CCP treatment.
7. Assessing the proportional odds assumption

To validate the goodness of fit for our Bayesian models, we drew replications of data from the joint posterior predictive distribution and compared these samples to observed data. We used the cumulative proportions of participants in each of the WHO score categories to measure the discrepancy between the original dataset and outcomes reconstructed from our Bayesian model. From the primary cumulative odds Bayesian model that we fitted, we sampled 10,000 simulations from the posterior density of the set of parameters. Then we generated one hypothetical replicated dataset of outcomes using each simulated set of parameters and the identical explanatory variables from original dataset. Finally, we estimated the Bayesian $P$ value by calculating the proportion of these 10,000 replicated datasets for which the test quantities equal or exceeds its realized value.
eTables and eFigures

eTable 1: Summary of posterior predictive checks for ten test statistics based on 10,000 replicated datasets.

| Treatment | CCP | Control |
|-----------|-----|---------|
| Test quantity: % subjects | T(Data<sup>or</sup>) | 95% CrI for T(Data<sup>or</sup>) | Bayesian P value | T(Data<sup>or</sup>) | 95% CrI for T(Data<sup>or</sup>) | Bayesian P value |
| WHO >= 10 | 0.08 | [0.04, 0.11] | 0.32 | 0.08 | [0.04, 0.12] | 0.30 |
| WHO >= 9 | 0.11 | [0.07, 0.17] | 0.48 | 0.14 | [0.07, 0.19] | 0.21 |
| WHO >= 8 | 0.15 | [0.10, 0.21] | 0.39 | 0.17 | [0.10, 0.23] | 0.27 |
| WHO >= 7 | 0.16 | [0.10, 0.23] | 0.38 | 0.19 | [0.11, 0.25] | 0.30 |
| WHO >= 6 | 0.23 | [0.14, 0.29] | 0.26 | 0.23 | [0.15, 0.32] | 0.40 |
| WHO >= 5 | 0.29 | [0.20, 0.37] | 0.35 | 0.31 | [0.21, 0.39] | 0.35 |
| WHO >= 4 | 0.31 | [0.22, 0.40] | 0.38 | 0.34 | [0.23, 0.42] | 0.35 |
| WHO >= 3 | 0.43 | [0.32, 0.53] | 0.42 | 0.46 | [0.34, 0.56] | 0.39 |
| WHO >= 2 | 0.76 | [0.64, 0.83] | 0.33 | 0.77 | [0.67, 0.85] | 0.42 |
| WHO >= 1 | 0.92 | [0.84, 0.95] | 0.29 | 0.93 | [0.86, 0.96] | 0.29 |

Abbreviations: CCP, COVID-19 Convalescent Plasma; CrI, credible interval; WHO, World Health Organization.
### eTable 2: Baseline Characteristics by Enrollment Sites and Treatment Group

|                | NYU      | Einstein | Yale   | Miami   | UT-Houston | UT-Tyler | JHU | Wisc |
|----------------|----------|----------|--------|---------|------------|----------|-----|------|
| n              | 380      | 160      | 47     | 106     | 146        | 100      | 1   | 1    |
| Enrollment quarters (%) |          |          |        |         |            |          |     |      |
| 2020 Q2        | 140 (36.8)| 30 (18.8)| 0 (0.0)| 0 (0.0) | 0 (0.0)    | 0 (0.0)  | 0   | 0    |
| 2020 Q3        | 12 (3.2) | 20 (12.5)| 4 (8.5)| 9 (8.5) | 17 (11.6)  | 51 (51.0)| 0   | 0    |
| 2020 Q4        | 130 (34.2)| 58 (36.2)| 37 (78.7)| 66 (62.3)| 76 (52.1)  | 40 (40.0)| 0   | 0    |
| 2021 Q5        | 98 (25.8)| 52 (32.5)| 6 (12.8)| 31 (29.2)| 53 (36.3)  | 9 (9.0)  | 1   | 1    |
| Age (mean (SD))| 65.5 (15.1)| 62.3 (15.4)| 64.6 (13.7)| 61.6 (14.8)| 54.6 (13.6)| 61.8 (14.6)| 83.0 (NA)| 47.0 (NA)|
| Age (categorical (%)) |        |          |        |         |            |          |     |      |
| <45 years      | 34 (8.9) | 26 (16.2)| 4 (8.5)| 15 (14.2)| 34 (23.3)  | 13 (13.0)| 0   | 0    |
| 45-64 years    | 138 (36.3)| 59 (36.9)| 19 (40.4)| 42 (39.6)| 83 (56.8)  | 34 (34.0)| 0   | 1    |
| 65-80 years    | 140 (36.8)| 53 (33.1)| 20 (42.6)| 40 (37.7)| 23 (15.8)  | 45 (45.0)| 0   | 0    |
| >80 years      | 68 (17.9)| 22 (13.8)| 4 (8.5)| 9 (8.5)  | 6 (4.1)    | 8 (8.0)  | 1   | 0    |
| Sex, Female (%)| 143 (37.6)| 74 (46.2)| 17 (36.2)| 37 (34.9)| 70 (47.9)  | 43 (43.0)| 1   | 0    |
| Blood type (%) |          |          |        |         |            |          |     |      |
| O              | 179 (47.1)| 89 (55.6)| 26 (55.3)| 59 (55.7)| 93 (63.7)  | 42 (42.0)| 1   | 0    |
| A              | 114 (30.0)| 39 (24.4)| 16 (34.0)| 28 (26.4)| 36 (24.7)  | 41 (41.0)| 0   | 0    |
| B              | 66 (17.4)| 23 (14.4)| 2 (4.3)| 19 (17.9)| 11 (7.5)   | 13 (13.0)| 0   | 1    |
| AB             | 20 (5.3)| 9 (5.6)  | 3 (6.4)| 0 (0.0)  | 5 (3.4)    | 4 (4.0)  | 0   | 0    |
| Unknown        | 1 (0.3)| 0 (0.0)  | 0 (0.0)| 0 (0.0)  | 1 (0.7)    | 0 (0.0)  | 0   | 0    |
| Time between symptom onset and randomization (%) |          |          |        |         |            |          |     |      |
| <4 days        | 46 (12.1)| 34 (21.2)| 3 (6.4)| 27 (25.5)| 19 (13.0)  | 23 (23.0)| 0   | 1    |
| 4-7 days       | 154 (40.5)| 84 (52.5)| 18 (38.3)| 45 (42.5)| 74 (50.7)  | 60 (60.0)| 1   | 0    |
| 8-11 days      | 125 (32.9)| 31 (19.4)| 18 (38.3)| 25 (23.6)| 34 (23.3)  | 14 (14.0)| 0   | 0    |
| 12-15 days     | 39 (10.3)| 6 (3.8)  | 2 (4.3)| 7 (6.6)  | 13 (8.9)   | 3 (3.0)  | 0   | 0    |
| >15 days       | 16 (4.2)| 5 (3.1)  | 5 (10.6)| 2 (1.9)  | 6 (4.1)    | 0 (0.0)  | 0   | 0    |
| NA             | 0 (0.0)| 0 (0.0)  | 1 (2.1)| 0 (0.0)  | 0 (0.0)    | 0 (0.0)  | 0   | 0    |
| WHO score at randomization, 5 (%) |        |          |        |         |            |          |     |      |
| 279 (73.4)     | 135 (84.4)| 26 (55.3)| 69 (65.1)| 84 (57.5)| 78 (78.0)  | 1 (100.0)| 1   | 0    |
| Condition       | JHU  | NYU  | UT   | Wisconsin  | WHO  | JHU  | NYU  | UT   | Wisconsin  | WHO  | JHU  | NYU  | UT   | Wisconsin  | WHO  |
|-----------------|------|------|------|------------|------|------|------|------|------------|------|------|------|------|------------|------|
| **High Risk (%)** | 273 (71.8) | 148 (92.5) | 42 (89.4) | 99 (93.4) | 119 (81.5) | 94 (94.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) |
| **Corticosteroids (%)** | 236 (62.1) | 117 (73.1) | 46 (97.9) | 102 (96.2) | 132 (90.4) | 87 (87.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) |
| **Remdesivir (%)** | 126 (33.2) | 111 (69.4) | 45 (95.7) | 95 (89.6) | 114 (78.1) | 45 (45.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) |
| **Diabetes (%)** | 115 (30.3) | 58 (36.2) | 17 (36.2) | 34 (32.1) | 65 (44.5) | 42 (42.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) |
| **Pulmonary (%)** | 35 (9.2) | 14 (8.8) | 7 (14.9) | 14 (13.2) | 4 (2.7) | 22 (22.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) |
| **Cardiovascular (%)** | 194 (51.1) | 59 (36.9) | 22 (46.8) | 33 (31.1) | 57 (39.0) | 38 (38.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) |

Abbreviations: JHU, Johns Hopkins University; NA, not available; NYU, New York University; Q, quarter; SD, standard deviation; UT, University of Texas; WHO, World Health Organization; Wisc, Wisconsin.
### eTable 3: Baseline Patient Characteristics by Enrollment Quarter

| Sites (merged) (%) | Enrollment quarters |  |  |  |  |
|-------------------|---------------------|---|---|---|---|
|                   | 2020Q2  | 2020Q3  | 2020Q4  | 2021Q5  |
| New York University| 140 (82.4) | 12 (10.6) | 130 (31.9) | 98 (39.0) |
| Einstein/Montefiore | 30 (17.6) | 20 (17.7) | 58 (14.3) | 52 (20.7) |
| Yale University    | 0 (0.0)   | 4 (3.5)   | 37 (9.1)   | 6 (2.4)   |
| University of Miami| 0 (0.0)   | 9 (8.0)   | 66 (16.2)  | 31 (12.4) |
| UT-Houston         | 0 (0.0)   | 17 (15.0) | 76 (18.7)  | 53 (21.1) |
| UT-Tyler           | 0 (0.0)   | 51 (45.1) | 40 (9.8)   | 9 (3.6)   |
| Johns Hopkins University | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.4) |
| Medical College of Wisconsin & Froedtert Hospital | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.4) |
| Age (mean (SD))    | 69.7 (14.6) | 59.0 (15.2) | 61.3 (15.3) | 60.7 (14.0) |
| Age (categorical) (%) |  |  |  |  |
| <45 years          | 10 (5.9)  | 20 (17.7) | 63 (15.5)  | 33 (13.1) |
| 45-64 years        | 54 (31.8) | 47 (41.6) | 158 (38.8) | 117 (46.6) |
| 65-80 years        | 57 (33.5) | 39 (34.5) | 145 (35.6) | 80 (31.9) |
| >80 years          | 49 (28.8) | 7 (6.2)   | 41 (10.1)  | 21 (8.4) |
| Sex, Female (%)    | 68 (40.0) | 45 (39.8) | 156 (38.3) | 116 (46.2) |
| Blood type (%)     |  |  |  |  |
| O                  | 84 (49.4) | 54 (47.8) | 225 (55.3) | 126 (50.2) |
| A                  | 52 (30.6) | 43 (38.1) | 111 (27.3) | 68 (27.1) |
| B                  | 27 (15.9) | 15 (13.3) | 48 (11.8)  | 45 (17.9) |
| AB                 | 7 (4.1)   | 1 (0.9)   | 21 (5.2)   | 12 (4.8) |
| Unknown            | 0 (0.0)   | 0 (0.0)   | 2 (0.5)    | 0 (0.0)   |
| Time between symptom onset and randomization (%) |  |  |  |  |
| <4 days            | 30 (17.6) | 27 (23.9) | 65 (16.0)  | 31 (12.4) |
| 4-7 days           | 44 (25.9) | 56 (49.6) | 186 (45.7) | 150 (59.8) |
| 8-11 days          | 45 (26.5) | 22 (19.5) | 122 (30.0) | 58 (23.1) |
| 12-15 days         | 34 (20.0) | 6 (5.3)   | 22 (5.4)   | 8 (3.2)   |
| >15 days           | 17 (10.0) | 2 (1.8)   | 11 (2.7)   | 4 (1.6)   |
| NA                 | 0 (0.0)   | 0 (0.0)   | 1 (0.2)    | 0 (0.0)   |
| WHO score at randomization, 5 (%) |  |  |  |  |
| High Risk (%)      | 135 (79.4) | 70 (61.9) | 288 (70.8) | 180 (71.7) |
| Corticosteroids (%)| 106 (62.4) | 101 (89.4) | 348 (85.5) | 222 (88.4) |
| Remdesivir (%)     | 40 (23.5) | 96 (85.0) | 366 (89.9) | 219 (87.3) |
| Diabetes (%)       | 2 (1.2)   | 53 (46.9) | 285 (70.0) | 197 (78.5) |
| Pulmonary (%)      | 60 (35.3) | 46 (40.7) | 128 (31.4) | 98 (39.0) |
| Cardiovascular (%) | 22 (12.9) | 13 (11.5) | 37 (9.1)   | 25 (10.0) |

Note: Corticosteroids include IV and PO corticosteroids at randomization. 
Abbreviations: NA, not available; Q, quarter; SD, standard deviation; UT, University of Texas Health Science Center; WHO, World Health Organization.
### Table 4: Cumulative Odds Model of WHO Scores at Day 14 by Subgroups

| Subgroup                                      | Posterior distribution of OR | 2.5% | Median | 97.5% | P(OR<1) | P(OR<0.8) |
|-----------------------------------------------|------------------------------|------|--------|-------|---------|-----------|
| Age < 65 (n=496)                              |                              | 0.740| 0.995  | 1.339 | 0.513   | 0.074     |
| Age ≥ 65 (n=430)                              |                              | 0.657| 0.891  | 1.206 | 0.773   | 0.247     |
| Symptom duration, 0-3 days (n=149)            |                              | 0.583| 0.919  | 1.461 | 0.638   | 0.279     |
| Symptom duration, 4-7 days (n=432)            |                              | 0.785| 1.072  | 1.464 | 0.332   | 0.033     |
| Symptom duration, > 7 days (n=345)            |                              | 0.645| 0.907  | 1.279 | 0.720   | 0.233     |
| Baseline WHO score, 5 (n=660)                 |                              | 0.711| 0.926  | 1.213 | 0.717   | 0.134     |
| Baseline WHO score, 6 (n=266)                 |                              | 0.665| 0.966  | 1.396 | 0.568   | 0.161     |
| Corticosteroids = No & Remdesivir = No (n=181)|                              | 0.475| 0.736  | 1.152 | 0.915   | 0.642     |
| Corticosteroids = No & Remdesivir = Yes (n=37)|                              | 0.651| 1.216  | 2.270 | 0.270   | 0.095     |
| Corticosteroids = Yes & Remdesivir = No (n=217)|                             | 0.471| 0.709  | 1.059 | 0.952   | 0.721     |
| Corticosteroids = Yes & Remdesivir = Yes (n=491)|                             | 0.891| 1.194  | 1.602 | 0.120   | 0.003     |
| Q2 (Apr-June 2020) (n=168)                    |                              | 0.519| 0.811  | 1.265 | 0.823   | 0.476     |
| Q3 (July-Sept 2020) (n=112)                   |                              | 0.542| 0.897  | 1.489 | 0.664   | 0.325     |
| Q4 (Oct-Dec 2020) (n=401)                     |                              | 0.717| 0.978  | 1.361 | 0.554   | 0.109     |
| Q5 (Jan-Mar 2021) (n=245)                     |                              | 0.747| 1.092  | 1.607 | 0.317   | 0.054     |
| Baseline SARS-CoV-2 IgG, Negative (n=239)     |                              | 0.775| 1.147  | 1.693 | 0.249   | 0.035     |
| Baseline SARS-CoV-2 IgG, Positive (n=482)     |                              | 0.716| 0.960  | 1.287 | 0.601   | 0.109     |
| Overall (n=926)                               |                              | 0.748| 0.936  | 1.175 | 0.721   | 0.081     |

Note: 2020 Q2 had NY sites only; the model for the group (Steroids = No & Remdesivir = Yes) controls for age and sex.

Abbreviations: OR, odds; ratio; Q, quarter; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
### eTable 5: Odds Ratios for Mortality at Day 14 by Subgroups

| Subgroup                                                                 | Posterior distribution of OR | 2.5% | Median | 97.5% | P(OR<1) | P(OR<0.8) |
|--------------------------------------------------------------------------|-------------------------------|------|--------|-------|---------|-----------|
| Age < 65 (n=496)                                                        |                               | 0.594| 1.096  | 1.995 | 0.384   | 0.161     |
| Age ≥ 65 (n=430)                                                        |                               | 0.563| 0.907  | 1.462 | 0.655   | 0.300     |
| Symptom duration, 0-3 days (n=149)                                      |                               | 0.565| 1.053  | 1.915 | 0.433   | 0.196     |
| Symptom duration, 4-7 days (n=432)                                      |                               | 0.644| 1.117  | 1.952 | 0.345   | 0.123     |
| Symptom duration, > 7 days (n=345)                                      |                               | 0.457| 0.810  | 1.429 | 0.757   | 0.483     |
| Baseline WHO score, 5 (n=660)                                           |                               | 0.508| 0.891  | 1.543 | 0.659   | 0.351     |
| Baseline WHO score, 6 (n=266)                                          |                               | 0.636| 1.068  | 1.776 | 0.404   | 0.134     |
| Corticosteroids = No & Remdesivir = No (n=181)                          |                               | 0.514| 0.936  | 1.756 | 0.580   | 0.306     |
| Corticosteroids = No & Remdesivir = Yes (n=37)                           |                               | 0.529| 1.035  | 2.042 | 0.461   | 0.228     |
| Corticosteroids = Yes & Remdesivir = sNo (n=217)                        |                               | 0.539| 1.003  | 1.876 | 0.496   | 0.242     |
| Corticosteroids = Yes & Remdesivir = Yes (n=491)                        |                               | 0.675| 1.195  | 2.078 | 0.265   | 0.079     |
| Q2 (Apr-June 2020) (n=168)                                              |                               | 0.453| 0.827  | 1.503 | 0.727   | 0.458     |
| Q3 (July-Sept 2020) (n=112)                                             |                               | 0.557| 1.029  | 1.967 | 0.461   | 0.211     |
| Q4 (Oct-Dec 2020) (n=401)                                               |                               | 0.542| 0.975  | 1.746 | 0.536   | 0.251     |
| Q5 (Jan-Mar 2021) (n=245)                                               |                               | 0.557| 1.024  | 1.824 | 0.467   | 0.216     |
| Baseline SARS-CoV-2 IgG, Negative (n=239)                                |                               | 0.572| 1.063  | 2.034 | 0.426   | 0.187     |
| Baseline SARS-CoV-2 IgG, Positive (n=482)                                |                               | 0.786| 1.366  | 2.388 | 0.132   | 0.029     |
| Overall (n=926)                                                         |                               | 0.639| 0.986  | 1.533 | 0.528   | 0.171     |

Note: 2020 Q2 had NY sites only; the model for the group (Steroids = No & Remdesivir = Yes) controls for age and sex.

Abbreviations: OR, odds ratio; Q, quarter; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
**eTable 6: Cumulative Odds Model of WHO Scores at Day 28 by Subgroups**

| Subgroup                                                                      | Posterior distribution of OR |         |         |         |         |
|------------------------------------------------------------------------------|------------------------------|---------|---------|---------|---------|
|                                                                              | 2.5% | Median | 97.5% | P(OR<1) | P(OR<0.8) |
| Age < 65 (n=496)                                                             | 0.761 | 1.026  | 1.383 | 0.431   | 0.048   |
| Age ≥ 65 (n=430)                                                              | 0.618 | 0.839  | 1.141 | 0.868   | 0.378   |
| Symptom duration, 0-3 days (n=149)                                           | 0.541 | 0.861  | 1.387 | 0.729   | 0.382   |
| Symptom duration, 4-7 days (n=432)                                           | 0.758 | 1.030  | 1.398 | 0.430   | 0.055   |
| Symptom duration, > 7 days (n=345)                                           | 0.649 | 0.914  | 1.283 | 0.694   | 0.227   |
| Baseline WHO score, 5 (n=660)                                                | 0.685 | 0.885  | 1.145 | 0.824   | 0.227   |
| Baseline WHO score, 6 (n=266)                                                | 0.684 | 1.000  | 1.467 | 0.499   | 0.121   |
| Corticosteroids = No & Remdesivir = No (n=181)                               | 0.409 | 0.651  | 1.020 | 0.968   | 0.815   |
| Corticosteroids = No & Remdesivir = Yes (n=37)                               | 0.662 | 1.248  | 2.299 | 0.247   | 0.081   |
| Corticosteroids = Yes & Remdesivir = No (n=217)                              | 0.561 | 0.841  | 1.268 | 0.789   | 0.407   |
| Corticosteroids = Yes & Remdesivir = Yes (n=491)                             | 0.851 | 1.143  | 1.541 | 0.192   | 0.009   |
| Q2 (Apr-June 2020) (n=168)                                                   | 0.464 | 0.722  | 1.127 | 0.926   | 0.671   |
| Q3 (July-Sept 2020) (n=112)                                                  | 0.499 | 0.830  | 1.386 | 0.765   | 0.440   |
| Q4 (Oct-Dec 2020) (n=401)                                                    | 0.720 | 0.989  | 1.386 | 0.524   | 0.095   |
| Q5 (Jan-Mar 2021) (n=245)                                                    | 0.814 | 1.183  | 1.744 | 0.188   | 0.020   |
| Baseline SARS-CoV-2 IgG, Negative (n=238)                                     | 0.810 | 1.200  | 1.791 | 0.184   | 0.021   |
| Baseline SARS-CoV-2 IgG, Positive (n=482)                                     | 0.699 | 0.931  | 1.240 | 0.680   | 0.155   |
| Overall (n=926)                                                              | 0.741 | 0.924  | 1.156 | 0.759   | 0.100   |

Note: 2020 Q2 had NY sites only; the model for the group (Steroids = No & Remdesivir = Yes) controls for age and sex.

Abbreviations: OR, odds, ratio; Q, quarter; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
eTable 7: Odds Ratio for Mortality at Day 28 by Subgroups

| Subgroup                                                   | Posterior distribution of OR | 2.5% | Median | 97.5% | P(OR<1) | P(OR<0.8) |
|------------------------------------------------------------|------------------------------|------|--------|-------|---------|-----------|
| Age < 65 (n=496)                                           |                              | 0.570| 0.959  | 1.633 | 0.559   | 0.249     |
| Age ≥ 65 (n=430)                                           |                              | 0.532| 0.813  | 1.234 | 0.832   | 0.472     |
| Symptom duration, 0-3 days (n=149)                         |                              | 0.537| 0.962  | 1.709 | 0.552   | 0.268     |
| Symptom duration, 4-7 days (n=432)                         |                              | 0.540| 0.884  | 1.425 | 0.695   | 0.345     |
| Symptom duration, > 7 days (n=345)                         |                              | 0.510| 0.872  | 1.495 | 0.690   | 0.373     |
| Baseline WHO score, 5 (n=660)                              |                              | 0.515| 0.833  | 1.362 | 0.767   | 0.432     |
| Baseline WHO score, 6 (n=266)                              |                              | 0.598| 0.946  | 1.487 | 0.596   | 0.228     |
| Corticosteroids = No & Remdesivir = No (n=181)             |                              | 0.436| 0.774  | 1.356 | 0.813   | 0.545     |
| Corticosteroids = No & Remdesivir = Yes (n=37)             |                              | 0.519| 1.004  | 1.961 | 0.496   | 0.256     |
| Corticosteroids = Yes & Remdesivir = No (n=217)            |                              | 0.489| 0.864  | 1.525 | 0.690   | 0.398     |
| Corticosteroids = Yes & Remdesivir = Yes (n=491)           |                              | 0.676| 1.131  | 1.904 | 0.320   | 0.096     |
| Q2 (Apr-June 2020) (n=168)                                |                              | 0.481| 0.832  | 1.438 | 0.739   | 0.448     |
| Q3 (July-Sept 2020) (n=112)                               |                              | 0.493| 0.925  | 1.751 | 0.593   | 0.329     |
| Q4 (Oct-Dec 2020) (n=401)                                 |                              | 0.592| 0.981  | 1.642 | 0.526   | 0.227     |
| Q5 (Jan-Mar 2021) (n=245)                                 |                              | 0.489| 0.823  | 1.445 | 0.744   | 0.461     |
| Baseline SARS-CoV-2 IgG, Negative (n=238)                  |                              | 0.534| 0.938  | 1.647 | 0.588   | 0.292     |
| Baseline SARS-CoV-2 IgG, Positive (n=482)                  |                              | 0.713| 1.190  | 1.961 | 0.254   | 0.069     |
| Overall (n=926)                                            |                              | 0.595| 0.863  | 1.245 | 0.782   | 0.342     |

Note: 2020 Q2 had NY sites only; the model for the group (Steroids = No & Remdesivir = Yes) controls for age and sex.
Abbreviations: OR, odds, ratio; Q, quarter; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
### eTable 8: Baseline Patient Characteristics by Remdesivir use at Randomization

| Remdesivir at Randomization | No          | Yes         | P       |
|-----------------------------|-------------|-------------|---------|
| n                           | 404         | 537         |         |
| Enrollment quarters (%)     |             |             | <0.001  |
| 2020 Q2                     | 168 (41.6)  | 2 (0.4)     |         |
| 2020 Q3                     | 60 (14.9)   | 53 (9.9)    |         |
| 2020 Q4                     | 122 (30.2)  | 285 (53.1)  |         |
| 2021 Q5                     | 54 (13.4)   | 197 (36.7)  |         |
| Age (mean (SD))             | 65.4 (15.2) | 60.1 (14.8) | <0.001  |
| Age (categorical) (%)       |             |             | <0.001  |
| <45 years                   | 43 (10.6)   | 83 (15.5)   |         |
| 45-64 years                 | 139 (34.4)  | 237 (44.1)  |         |
| 65-80 years                 | 148 (36.6)  | 173 (32.2)  |         |
| >80 years                   | 74 (18.3)   | 44 (8.2)    |         |
| Sex, Female (%)             |             |             | 0.573   |
| Blood type (%)              |             |             |         |
| O                           | 202 (50.0)  | 287 (53.4)  |         |
| A                           | 124 (30.7)  | 150 (27.9)  |         |
| B                           | 63 (15.6)   | 72 (13.4)   |         |
| AB                          | 14 (3.5)    | 27 (5.0)    |         |
| Unknown                     | 1 (0.2)     | 1 (0.2)     |         |
| Time between symptom onset and randomization (%) | | | <0.001 |
| <4 days                     | 81 (20.0)   | 72 (13.4)   |         |
| 4-7 days                    | 153 (37.9)  | 283 (52.8)  |         |
| 8-11 days                   | 103 (25.5)  | 144 (26.9)  |         |
| 12-15 days                  | 42 (10.4)   | 28 (5.2)    |         |
| >15 days                    | 25 (6.2)    | 9 (1.7)     |         |
| WHO score at randomization, 5 (%) | 322 (79.7) | 351 (65.4) | <0.001  |
| High Risk (%)               | 313 (77.5)  | 464 (86.4)  | <0.001  |
| Diabetes (%)                | 149 (36.9)  | 183 (34.1)  | 0.411   |
| Pulmonary (%)               | 47 (11.6)   | 50 (9.3)    | 0.293   |
| Cardiovascular (%)          | 205 (50.7)  | 199 (37.1)  | <0.001  |

Abbreviations: Q, quarter; SD, standard deviation; WHO, World Health Organization.
**eTable 9: Baseline Patient Characteristics by Corticosteroids use at Randomization**

|                          | Corticosteroids at Randomization |       |       |  P         |
|--------------------------|---------------------------------|-------|-------|-----------|
|                          | No                              | Yes   |       | <0.001    |
| n                        | 220                             | 721   |       |           |
| Enrollment quarters (%)  |                                 |       |       |           |
| 2020 Q2                  | 130 (59.1)                      | 40 (5.5) |       |           |
| 2020 Q3                  | 17 (7.7)                        | 96 (13.3) |     |           |
| 2020 Q4                  | 41 (18.6)                       | 366 (50.8) |   |           |
| 2021 Q5                  | 32 (14.5)                       | 219 (30.4) |   |           |
| Age (mean (SD))          | 67.8 (15.3)                     | 60.7 (14.8) | <0.001 |           |
| Age (categorical) (%)    |                                 |       |       | <0.001    |
| <45 years                | 19 (8.6)                        | 107 (14.8) |     |           |
| 45-64 years              | 73 (33.2)                       | 303 (42.0) |   |           |
| 65-80 years              | 77 (35.0)                       | 244 (33.8) |   |           |
| >80 years                | 51 (23.2)                       | 67 (9.3) |       |           |
| Sex, Female (%)          | 87 (39.5)                       | 298 (41.3) | 0.694 |           |
| Blood type (%)           |                                 |       |       | 0.739     |
| O                        | 115 (52.3)                      | 374 (51.9) |     |           |
| A                        | 67 (30.5)                       | 207 (28.7) |   |           |
| B                        | 30 (13.6)                       | 105 (14.6) |   |           |
| AB                       | 7 (3.2)                         | 34 (4.7) |       |           |
| Unknown                  | 1 (0.5)                         | 1 (0.1) |       |           |
| Time between symptom onset and randomization (%) | | | | <0.001 |
| <4 days                  | 48 (21.8)                       | 105 (14.6) |     |           |
| 4-7 days                 | 81 (36.8)                       | 355 (49.3) |   |           |
| 8-11 days                | 46 (20.9)                       | 201 (27.9) |   |           |
| 12-15 days               | 30 (13.6)                       | 40 (5.6) |       |           |
| >15 days                 | 15 (6.8)                        | 19 (2.6) |       |           |
| WHO score at randomization, 5 (%) | 187 (85.0) | 486 (67.4) | <0.001 |
| High Risk (%)            | 162 (73.6)                      | 615 (85.3) | <0.001 | |
| Diabetes (%)             | 83 (37.7)                       | 249 (34.5) | 0.431 | |
| Pulmonary (%)            | 22 (10.0)                       | 75 (10.4) | 0.964 | |
| Cardiovascular (%)       | 126 (57.3)                      | 278 (38.6) | <0.001 | |

Note: Corticosteroids include IV and PO corticosteroids at randomization.
Abbreviations: Q, quarter; SD, standard deviation; WHO, World Health Organization.
### eTable 10: CCP SARS-CoV-2 IgG and Neutralizing titers by Quarters of Enrollment

|                     | Total | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q5 | P value ≤ |
|---------------------|-------|---------|---------|---------|---------|-----------|
| Number randomized to CCP | 468   | 84      | 60      | 199     | 125     |           |
| CCP IgG EC<sub>50</sub>, median (IQR) | 1:2,016 (916-4,229; n=359) | 1:2,047 (677-5,400; n=69) | 1:1,610 (1,018-2,679; n=50) | 1:1,439 (611-3,054; n=146) | 1:3,596 (2,179-6,097; n=94) | <0.0001 |
| CCP Nt, median (IQR) | 1:93 (48-213; n=352) | 1:175 (76-379; n=58) | 1:73 (49-103; n=46) | 1:79 (35-178; n=166) | 1:106 (63-235; n=82) | <0.0001 |

Abbreviations: CCP, COVID-19 Convalescent Plasma; EC<sub>50</sub>, half-maximal effective concentration; IQR, interquartile range; Nt, neutralizing titer; Q, quarters; SARS-CoV-2, severe acute respiratory syndrome coronavirus.

<sup>a</sup> Kruskal-Wallis rank sum test
**eTable 11: Baseline Characteristics and Day 14/28 Outcomes by Baseline SARS-CoV-2 IgG status and Treatment Group**

| Baseline SARS-CoV-2 IgG Negative | Baseline SARS-CoV-2 IgG Positive |
|----------------------------------|----------------------------------|
| Placebo                          | CCP                              |
| Placebo                          | CCP                              |

### Baseline characteristics

| Enrollment quarters (%) |
|-------------------------|
| 2020 Q2 | 3 (2.6) | 7 (5.6) | 31 (12.0) | 21 (9.2) |
| 2020 Q3 | 17 (14.5) | 21 (16.8) | 27 (10.5) | 28 (12.3) |
| 2020 Q4 | 56 (47.9) | 61 (48.8) | 130 (50.4) | 118 (51.8) |
| 2021 Q5 | 41 (31.5) | 36 (28.8) | 70 (27.1) | 61 (26.8) |

### Age (mean (SD))

| Age (categorical) (%) |
|-----------------------|
| <45 years | 11 (9.4) | 17 (13.6) | 42 (16.3) | 37 (16.2) |
| 45-64 years | 47 (40.2) | 54 (43.2) | 104 (40.3) | 98 (43.0) |
| 65-80 years | 46 (39.3) | 45 (36.0) | 86 (33.3) | 66 (28.9) |
| >80 years | 13 (11.0) | 9 (7.2) | 26 (10.1) | 27 (11.8) |

### Sex, Female (%)

| Blood type (%) |
|----------------|
| O | 66 (56.4) | 57 (45.6) | 142 (55.0) | 119 (52.2) |
| A | 33 (28.2) | 42 (33.6) | 71 (27.5) | 60 (26.3) |
| B | 14 (12.0) | 22 (17.6) | 36 (13.6) | 35 (15.4) |
| AB | 4 (3.4) | 4 (3.2) | 9 (3.5) | 14 (6.1) |
| Unknown | 0 (0.0) | 0 (0.0) | 1 (0.4) | 0 (0.0) |

### Time between symptom onset and randomization (%)

| Remdesivir/Corticosteroids (%) |
|--------------------------------|
| None | 13 (11.1) | 10 (8.0) | 32 (12.4) | 27 (11.8) |
| Corticosteroids only | 38 (32.5) | 32 (25.6) | 56 (21.7) | 53 (23.2) |
| Remdesivir only | 6 (5.1) | 9 (7.2) | 9 (3.5) | 4 (1.8) |
| Both | 60 (51.3) | 74 (59.2) | 121 (46.9) | 96 (42.1) |
| Diabetes (%) | 45 (38.5) | 43 (34.4) | 87 (33.7) | 77 (33.8) |
| Pulmonary (%) | 16 (13.7) | 17 (13.6) | 23 (8.9) | 22 (9.6) |
| Cardiovascular (%) | 55 (47.0) | 46 (38.8) | 103 (39.9) | 90 (39.5) |

### Primary outcome

| WHO score at day 14 (%) |
|------------------------|
| 0 | 6 (5.1) | 7 (5.6) | 19 (7.4) | 22 (9.6) |
| 1 | 18 (15.4) | 15 (12.0) | 46 (17.8) | 43 (18.9) |
| 2 | 38 (32.5) | 37 (29.6) | 88 (34.1) | 79 (34.6) |
| 3 | 14 (12.0) | 18 (14.4) | 29 (11.2) | 24 (10.5) |
| 4 | 2 (1.7) | 5 (4.0) | 11 (4.3) | 2 (0.9) |
| 5 | 4 (3.4) | 6 (4.8) | 22 (8.5) | 13 (5.7) |
|     | 6 (6.8) | 12 (9.6) | 7 (2.7) | 10 (4.4) |
|-----|---------|----------|---------|----------|
| 7   | 2 (1.7) | 3 (2.4)  | 1 (0.4) | 1 (0.4)  |
| 8   | 5 (4.3) | 8 (6.4)  | 6 (2.3) | 7 (3.1)  |
| 9   | 9 (7.7) | 6 (4.8)  | 14 (5.4)| 6 (2.6)  |
| 10  | 9 (7.7) | 7 (5.6)  | 13 (5.0)| 19 (8.3) |
| NA  | 2 (1.7) | 1 (0.8)  | 2 (0.8) | 2 (0.9)  |

**Secondary outcome**

| WHO score at day 28 (%) | 0 (17.1) | 18 (14.4) | 55 (21.3) | 56 (24.6) |
|-------------------------|----------|-----------|-----------|-----------|
| 1                       | 22 (18.8)| 16 (12.8) | 51 (19.8) | 46 (20.2) |
| 2                       | 30 (25.6)| 38 (30.4) | 72 (27.9) | 65 (28.5) |
| 3                       | 9 (7.7)  | 16 (12.8) | 27 (10.5) | 14 (6.1)  |
| 4                       | 1 (0.9)  | 4 (3.2)   | 4 (1.6)   | 1 (0.4)   |
| 5                       | 1 (0.9)  | 4 (3.2)   | 5 (1.9)   | 4 (1.8)   |
| 6                       | 2 (1.7)  | 1 (0.8)   | 4 (1.6)   | 4 (1.8)   |
| 7                       | 3 (2.6)  | 1 (0.8)   | 2 (0.8)   | 2 (0.9)   |
| 8                       | 3 (2.6)  | 1 (0.8)   | 4 (1.6)   | 1 (0.4)   |
| 9                       | 2 (1.7)  | 7 (5.6)   | 6 (2.3)   | 5 (2.2)   |
| 10                      | 21 (17.9)| 18 (14.4) | 26 (10.1) | 28 (12.3) |
| NA                      | 3 (2.6)  | 1 (0.8)   | 2 (0.8)   | 2 (0.9)   |

Note: Corticosteroids include IV and PO corticosteroids at randomization.
Abbreviations: NA, not available; Q, quarter; SD, standard deviation; WHO, World Health Organization.
### Table 12: Adverse events and Serious Adverse events

|                          | Placebo | CCP   | P value |
|--------------------------|---------|-------|---------|
| **n**                    | 473     | 468   |         |
| **Adverse events (%)**   |         |       |         |
| **Transfusion reaction** |         |       |         |
| Transfusion reaction     |         |       |         |
| TACO                     | 0 (0.0) | 0 (0.0) |         |
| TRALI                    | 0 (0.0) | 0 (0.0) |         |
| Transfusion reaction (other than TRALI or TACO) (%) | 2 (0.4) | 8 (1.7) | 0.06   |
| **Arterial thromboembolism** | 11 (2.3) | 8 (1.7) | 0.64   |
| **Venous thromboembolism** | 31 (6.6) | 37 (7.9) | 0.45   |
| **Patients with any adverse events (excluding other transfusion reactions)** | 39 (8.2) | 44 (9.4) | 0.57   |
| **Bleeding**             | 35 (7.4) | 41 (8.8) | 0.47   |
| **Infection**            | 124 (26.2) | 110 (23.5) | 0.37   |
| **Hospital readmission** | 67 (14.2) | 59 (12.6) | 0.50   |

Abbreviations: CCP, COVID-19 convalescent plasma; TACO, transfusion-associated circulatory overload; TRALI, transfusion-related acute lung injury.
eFigure 1: Trace Plots of Model Convergence

Day 14 cumulative odds model

Day 14 logistic model

Day 28 cumulative odds model

Day 28 logistic model
eFigure 2. Observed cumulative probability with predicted 95% credible interval by treatment group.
eFigure 3. Clinical Outcomes among Patients Treated with Convalescent Plasma and Placebo 14 and 28 Days after Randomization by Enrollment Quarter

Distribution of clinical status at 14 and 28 days after randomization by enrollment quarter based on 11-point ordinal scale shown by cumulative OR (curves) and 11 point WHO scores (stacked bars). ECMO, extracorporeal membrane oxygenation; HFNC, high flow nasal cannula; MV, mechanical ventilation; NIV, non-invasive ventilation. Stacked bar blank cells < 3%.
eFigure 4: Cumulative OR for WHO ordinal scale and OR for mortality at Day 14 in indicated subgroups
eFigure 5: Cumulative OR for WHO ordinal scale and OR for mortality at Day 28 in indicated subgroups
eFigure 6: Posterior Probability of Mortality at Day 14 of placebo and CCP recipients in indicated subgroups without adjustment for any covariates.
eFigure 7: Posterior Probability of Mortality at Day 28 of placebo and CCP recipients in indicated subgroups without adjustment for any covariates
**eFigure 8: Clinical Outcome in Placebo and CCP Groups Dichotomized by Median CCP SARS-CoV-2 IgG EC$_{50}$ at 14 and 28 days after randomization**

Distribution of clinical status of placebo and CCP recipients based on WHO score at 14 (top) and 28 (bottom) days after randomization. SARS-CoV-2 IgG EC$_{50}$ was dichotomized at the median (1:2,016); values <1:2,016 were shown as low EC$_{50}$; values >1:2,016 shown as high EC$_{50}$. N=473 (placebo); 468 (CCP); 180 (low EC$_{50}$); 179 (high EC$_{50}$). EC$_{50}$ indicates half-maximal effective concentration. Blank cells < 3%.
References

1. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis.* 2020;20(8):e192-e197.

2. Yoon HA, Bartash R, Gendlina I, et al. Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC. *JCI Insight.* 2021.

3. Bortz RH, 3rd, Florez C, Laudermilch E, et al. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. *mSphere.* 2021;6(2).

4. Recommendations for Investigational COVID-19 Convalescent Plasma, 2020. Available from: https://www.fda.gov/media/141480/download. Last accessed Sept. 22, 2021.

5. New York SARS-CoV Microsphere Immunoassay for Antibody Detection. https://www.fda.gov/media/137541/download. Last accessed Sept. 22, 2021.

6. Herrera NG, Morano NC, Celikgil A, et al. Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. *ACS Omega.* 2021;6(1):85-102.

7. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science.* 2020;367(6483):1260-1263.

8. Dieterle ME, Haslwanter, D., Bortz III., R.H., Wirchnianski, A.S., Lasso,, G. V, O., Abbasi, S.A., Fels, J.M., Laudermilch, E., Florez, C., Mengotto, A., Kimmel, D., Malonis RJ, Georgiev, G., Quiroz, J., Barnhill, J., Pirofski, L.-a., Daily, J.P., Dye, J.M., Lai, J.R., Herbert AS, Chandran, K., Jangra, R.K. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. *Cell Host and Microbe* (2020). 2020.
9. Gelman A, John B. Carlin, Hal S. Stern, David B. Dunson, Aki Vehtari, and Donald B. Rubin. Bayesian data analysis. *CRC press*, 2013.